220 related articles for article (PubMed ID: 19821827)
21. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
23. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
26. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
27. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
Uyttebroeck A; Suciu S; Laureys G; Robert A; Pacquement H; Ferster A; Marguerite G; Mazingue F; Renard M; Lutz P; Rialland X; Mechinaud F; Cavé H; Baila L; Bertrand Y;
Eur J Cancer; 2008 Apr; 44(6):840-6. PubMed ID: 18342502
[TBL] [Abstract][Full Text] [Related]
28. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Deenik W; Beverloo HB; van der Poel-van de Luytgaarde SC; Wattel MM; van Esser JW; Valk PJ; Cornelissen JJ
Leukemia; 2009 Mar; 23(3):627-9. PubMed ID: 18987655
[No Abstract] [Full Text] [Related]
29. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
30. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
[TBL] [Abstract][Full Text] [Related]
31. Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
Sun XF; Zhen ZJ; Lui DG; Xia Y; He YJ; Wang ZH; Lin JY; Guan ZZ
Eur J Haematol; 2006 Nov; 77(5):365-71. PubMed ID: 16879606
[TBL] [Abstract][Full Text] [Related]
32. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
34. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
Burkhardt B; Zimmermann M; Oschlies I; Niggli F; Mann G; Parwaresch R; Riehm H; Schrappe M; Reiter A;
Br J Haematol; 2005 Oct; 131(1):39-49. PubMed ID: 16173961
[TBL] [Abstract][Full Text] [Related]
35. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
[No Abstract] [Full Text] [Related]
36. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
37. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
38. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
Hagemeijer A; Graux C
Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion.
Oliveira JL; Kumar R; Khan SP; Law ME; Erickson-Johnson M; Oliveira AM; Ketterling RP; Dogan A
Pediatr Blood Cancer; 2011 Mar; 56(3):467-9. PubMed ID: 21225930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
